150 related articles for article (PubMed ID: 35656509)
21. The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.
Ying X; You G; Shao R
Transl Cancer Res; 2024 May; 13(5):2408-2418. PubMed ID: 38881915
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Friedes C; Yegya-Raman N; Zhang S; Iocolano M; Cohen RB; Aggarwal C; Thompson JC; Marmarelis ME; Levin WP; Cengel KA; Ciunci CA; Singh AP; D'Avella C; Davis CW; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2024 Jan; 25(1):50-60.e6. PubMed ID: 37813713
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
24. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
25. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664137
[TBL] [Abstract][Full Text] [Related]
26. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
[TBL] [Abstract][Full Text] [Related]
28. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
29. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
30. Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer.
Papageorgiou GI; Skouteris N; Kosma A; Markouizou A; Charalampakis N
Rev Recent Clin Trials; 2023; 18(2):146-155. PubMed ID: 37046193
[TBL] [Abstract][Full Text] [Related]
31. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
32. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
36. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
[TBL] [Abstract][Full Text] [Related]
37. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
38. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
Front Oncol; 2022; 12():863609. PubMed ID: 35494057
[TBL] [Abstract][Full Text] [Related]
39. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
40. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
Triggiani L; Mazzola R; Magrini SM; Ingrosso G; Borghetti P; Trippa F; Lancia A; Detti B; Francolini G; Matrone F; Bortolus R; Fanetti G; Maranzano E; Pasqualetti F; Paiar F; Bonù ML; Magli A; Bruni A; Mazzeo E; Franzese C; Scorsetti M; Alongi F; Jereczek-Fossa BA; Ost P; Buglione M
World J Urol; 2019 Dec; 37(12):2631-2637. PubMed ID: 30859273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]